Everus Construction (ECG) Q2 2026 Earnings Call Transcript

Everus Construction Group reported Q2 2026 revenue of $1.23B (+34% YoY; +30% organic), with EBITDA rising to $128.6M (+53%) and EBITDA margin up 130 bps to 10.4%. Backlog reached a record $4.55B (+53% YoY), and free cash flow for the first half climbed to $167.0M vs. $6.5M a year ago, supported by $157.4M unrestricted cash and low net leverage of 0.3x. The company raised 2026 guidance to revenue of $4.5B–$4.7B and EBITDA of $410M–$425M (up from $345M–$360M), while highlighting ongoing expansion of its modular off-site capabilities via the SE&M acquisition and a pending Epsilon Industries deal.

Analysis

ECG is morphing from a contractor with good execution into a scarcity asset tied to the AI/fab buildout and labor-saving modular delivery. That matters because the market typically pays a premium for businesses that can convert scarce skilled labor into repeatable throughput; if that operating model holds, the multiple can re-rate before the earnings base fully catches up. The second-order winner is the ecosystem around hyperscale/data-center construction: suppliers of prefabricated components, electrical gear, and engineering labor should see tighter pricing and better utilization, while smaller local contractors without scale or modular capability may get squeezed.

The bigger issue is durability, not near-term upside. With a large share of backlog expected to convert inside 12 months, the next catalyst window is 1-2 quarters: any slowdown in hyperscale pacing, semiconductor capex, or project starts would show up quickly in revenue growth and mix, especially since the company is leaning on M&A to sustain momentum. T&D looks like a quieter, lower-growth counterbalance; if utility spend softens, the market may start treating ECG as a single-factor data-center proxy rather than a diversified infrastructure compounder.

Contrarian take: consensus may be underestimating how much of the current enthusiasm is already capitalized into backlog and guidance. The bullish case is real, but the stock is vulnerable if margin expansion proves timing-driven rather than structural or if acquisition integration absorbs management bandwidth. The clean falsifier is a guide-down in EBITDA margin or a deceleration in backlog conversion over the next two quarters; absent that, pullbacks should be buyable rather than chased.

Key Decisions for Investors

• Buy ECG on any post-earnings pullback over the next 1-3 weeks; thesis is that the market will pay for a modular/data-center compounder before the next few quarters of growth are fully visible. Risk/reward is attractive if the stock de-rates only on broad industrial weakness, not on company-specific execution.
• Pair trade: long ECG / short J or PWR for 1-3 months if you want to isolate modular data-center exposure against broader infrastructure beta. ECG should outperform if hyperscale/fab spending stays firm and labor productivity remains the key differentiator.
• Watch-and-buy alert: if ECG trades down 8-12% without a margin or guidance miss, use that as entry for a 6-12 month long. Falsifier is any evidence that the 8.5% back-half margin guide is not sustainable.
• For options, consider ECG call spreads 3-6 months out rather than outright calls if liquidity is adequate; the upside is continued multiple expansion, but M&A and project-timing noise make defined risk preferable.
• Do not chase T&D-related proxies here; if the market starts valuing ECG as a pure data-center contractor, that is a warning sign to trim on strength rather than add.